isosulfan blue
Trade name: lymphazurin
Approved
Jul 29, 1981
Isosulfan Blue is a synthetic visual lymphatic imaging agent. Injected into the periphery of the tumor site, isosulfan blue localizes to the lymphatic system and aids in the surgical identification of tumor sentinel nodes which stain blue. The chemical name of isosulfan blue is N-[4-[[4-(diethylamino)phenyl] (2,5-disulfophenyl) methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium hydroxide, inner salt, sodium salt. Isosulfan blue is a greenish blue color hygroscopic powder. Isosulfan blue injection 1% is a contrast agent for the delineation of lymphatic vessels. Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities. — NCATS
Clinical trial activity
16 trials · 18 clinical orgs · 13 marketing orgs
Earliest trial started Apr 1, 1997 (NCT00003186)
Timeline
1980s
2010s
- Jul 20, 2010
Mylan — Marketing Organization
- Feb 2, 2016
Aurobindo Pharma — Marketing Organization
- Feb 2, 2016
Eugia Pharma — Marketing Organization
- Jan 1, 2019
Earliest Phase 3 Sponsor(trial)
- Jan 16, 2019
Beloteca Inc — Marketing Organization
- Jul 12, 2019
Somerset Pharmaceuticals — Marketing Organization
- Jul 12, 2019
ANDA Repository — Marketing Organization
2020s
- Nov 3, 2021
Meitheal — Marketing Organization
- Nov 3, 2021
Eu Yan Sang — Marketing Organization
- Sep 8, 2022
Fresenius — Marketing Organization
- Sep 16, 2022
MSN Laboratories — Marketing Organization
- May 17, 2023
Sankyo — Marketing Organization
- May 17, 2023
Daiichi Sankyo — Marketing Organization
Indications
Approved for
Mechanism of action
- Serum albuminBINDING AGENT
ALB binding agent
Approval history
- approvedJul 29, 1981
Chemistry & pharmacology
SMILES
CCN(CC)c1ccc(cc1)C(=C2C=CC(=[N+](CC)CC)C=C2)c3cc(ccc3S(=O)(=O)O)S(=O)(=O)O- Mol. weight
- 545.7 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL1615783 ↗
- NCATSNS6Q291771 ↗
- ChEMBLCHEMBL1201275 ↗
- ChEMBLCHEMBL1200859 ↗
Also known as
- ethanaminium, n-(4-((4-(diethylamino)phenyl)(2,5-disulfophenyl)methylene)-2,5-cyclohexadien-1-ylidene)-n-ethyl-, hydroxide, inner salt, sodium salt
- iso-sulfan blue
- iso-sulfan blue
- isosulfan blue
- isosulfan blue
- isosulfan blue
- isosulfan blue
- isosulfan blue
- isosulfan blue
- isosulfan blue
- isosulfan blue
- iso-sulphan blue
- lymphazurin
- lymphazurin
- lymphazurin
- lymphazurin
- lymphazurin
- lymphazurin blue
- p-1888
- p-1888
- p-4125
- p-4125
- vital blue dye
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03927027 | Phase 3 | May 31, 2019 | National Cancer Institute (NCI), University of Texas, Galveston |
| NCT02509598 | Phase 2 | Aug 1, 2015 | Cardinal Health |
| NCT02336737 | N/A | Jan 1, 2015 | Endomagnetics Inc, Regulatory and Clinical Research Institute Inc, University of California, San Francisco |
| NCT01939028 | N/A | Jul 1, 2013 | Case Western Reserve University, National Cancer Institute (NCI) |
| NCT01038908 | Phase 2 | Jun 30, 2013 | University of British Columbia |
| NCT01898403 | N/A | Jun 1, 2013 | National Cancer Institute (NCI), Stanford University |
| NCT01818739 | N/A | Feb 1, 2013 | Ohio State University |
| NCT01771666 | Phase 2 | Jul 31, 2012 | Stanford University |
| NCT00932035 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2009 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT00717886 | N/A | Jun 1, 2008 | Cornell University |
| NCT00438477 | N/A | Jun 1, 2005 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT00070317 | N/A | Jun 1, 2004 | Gynecologic Oncology Group, National Cancer Institute (NCI) |
| NCT00450723 | N/A | May 1, 2004 | University of Miami |
| NCT00625625 | Phase 2 | Mar 1, 2004 | John Wayne Cancer Institute, National Cancer Institute (NCI) |
| NCT00012168 | N/A | May 1, 1999 | National Cancer Institute (NCI), New York University |
| NCT00003186 | N/A | Apr 1, 1997 | National Cancer Institute (NCI), State University of New York, Buffalo, University of Texas at Houston |
Organizations
Research & Development (18)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 9 | 1 | 3 | 1997 |
| Stanford University | Academic/Hospital | 2 | 2 | 2 | 2012 |
| University of Texas at Houston | Academic/Hospital | 2 | 1 | 1 | 1997 |
| Cardinal Health | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Case Western Reserve University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Endomagnetics Inc | For profit | 1 | 1 | 1 | 2015 |
| Gynecologic Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2004 |
| John Wayne Cancer Institute | Academic/Hospital | 1 | 1 | 1 | 2004 |
| New York University | Academic/Hospital | 1 | 1 | 1 | 1999 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Regulatory and Clinical Research Institute Inc | For profit | 1 | 0 | 1 | 2015 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 1 | 1 | 1997 |
| University of British Columbia | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Miami | Academic/Hospital | 1 | 1 | 1 | 2004 |
| University of Texas, Galveston | Academic/Hospital | 1 | 0 | 1 | 2019 |
Marketing (15)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| ANDA Repository | For profit | MKTG | Jul 12, 2019 |
| Aurobindo Pharma | For profit | MKTG | Feb 2, 2016 |
| Beloteca Inc | For profit | MKTG | Jan 16, 2019 |
| Beloteca Inc | For profit | SYN | Jan 16, 2019 |
| Covidien | For profit | NDA2 | Jul 29, 1981 |
| Covidien | For profit | NDA | Jul 29, 1981 |
| Daiichi Sankyo | For profit | MKTG | May 17, 2023 |
| Eu Yan Sang | For profit | MKTG | Nov 3, 2021 |
| Eugia Pharma | For profit | MKTG | Feb 2, 2016 |
| Fresenius | For profit | MKTG | Sep 8, 2022 |
| MSN Laboratories | For profit | MKTG | Sep 16, 2022 |
| Meitheal | For profit | MKTG | Nov 3, 2021 |
| Mylan | For profit | MKTG | Jul 20, 2010 |
| Sankyo | For profit | MKTG | May 17, 2023 |
| Somerset Pharmaceuticals | For profit | MKTG | Jul 12, 2019 |